John Vargas, DO
General Practice · Midland, MINPI 1063692044
Payments from drug & device makers
Across 1,057 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Supernus Pharmaceuticals, Inc.$1K
- AbbVie$1K
- Pfizer$1K
- GSK$1K
- Grifols USA, LLC$1K
- plus $10K from 41 others
What the payments were for
- Food & beverage$18,92699%
- Education$1931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,119 in reported general payments places this provider in the 95th percentile of 3,051 general practice providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 147 | $162,615 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 160 | $113,920 |
| IngrezzaValbenazine Tosylate | 14 | $108,720 |
| OzempicSemaglutide | 76 | $82,911 |
| JardianceEmpagliflozin | 101 | $68,800 |
| GemtesaVibegron | 121 | $68,053 |
| EliquisApixaban | 75 | $66,566 |
| Abilify MaintenaAripiprazole | 24 | $63,317 |
| AuvelityDextromethorphan Hbr/Bupropion | 34 | $38,184 |
| FarxigaDapagliflozin Propanediol | 52 | $37,180 |
| XareltoRivaroxaban | 34 | $29,339 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,377 | $27,784 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $25,788 |
| MounjaroTirzepatide | 23 | $24,434 |
| LinzessLinaclotide | 27 | $23,220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $581 | $187,049170 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,203 | $123,176181 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $385 | $108,72014 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $316 | $105,682155 claims |
| Novo NordiskOzempic, Rybelsus | $582 | $96,85191 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $2,341 | $79,92036 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $694 | $68,053121 claims |
| PfizerEliquis | $1,222 | $66,56675 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $515 | $52,63591 claims |
| Axsome Therapeutics, Inc.Auvelity | $552 | $38,18434 claims |
| AbbVieLinzess | $1,443 | $23,22027 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $250 | $13,81112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,051 general practice providers in Michigan.
Other general practice in Midland
- Anil PrasadTaylor$1.7M
- Sadeer DaoodDearborn$1.1M
- Shakib HalabuWest Bloomfield$1.1M
- Dennis FasbinderAnn Arbor$758K
- Christian GrothAnn Arbor$283K
- Kevin BoneSaginaw$125K
- David JulianiRochester Hills$106K
- Marie FluentAnn Arbor$106K
- Howard KormanRoyal Oak$93K
- Hans SchwarzSterling Heights$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.